| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.22 | 0.2 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | JQ-1 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.21 | 0.2 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.086 | 0.2 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.19 | 0.2 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |